C07K 14/7156
For interferons [ifn]
Official title: {for interferons [IFN]}
C07K14/7156 (For interferons [ifn]) appears on 79 US grants and 157 published applications in this corpus.
Search patents in C07K- Granted patents
- 79
- Published applications
- 157
- Assignees
- 77
- Inventors
- 226
- Latest grant
- 5 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 4 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 2 |
| 2003 | 2 | 5 |
| 2004 | 1 | 2 |
| 2005 | 0 | 3 |
| 2006 | 1 | 4 |
| 2007 | 2 | 14 |
| 2008 | 4 | 1 |
| 2009 | 4 | 6 |
| 2010 | 5 | 4 |
| 2011 | 2 | 7 |
| 2012 | 2 | 3 |
| 2013 | 1 | 2 |
| 2014 | 1 | 3 |
| 2015 | 0 | 1 |
| 2016 | 2 | 5 |
| 2017 | 0 | 0 |
| 2018 | 3 | 2 |
| 2019 | 4 | 8 |
| 2020 | 2 | 6 |
| 2021 | 4 | 9 |
| 2022 | 2 | 9 |
| 2023 | 6 | 19 |
| 2024 | 11 | 21 |
| 2025 | 8 | 13 |
| 2026 | 4 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Activatable cytokine polypeptides and methods of use thereof5 May 2026US 12,617,829 B2Werewolf Therapeutics, Inc.
- Engineered T cells31 Mar 2026US 12,590,136 B2Medigene Immunotherapies GmbH
- Chimeric antigen receptor, macrophage expressing same, method for adjusting macrophage polarization, and use thereof3 Feb 2026US 12,540,182 B2Zhejiang University
- CD20 binding single domain antibodies3 Feb 2026US 12,540,192 B2Universiteit Gent
- CLEC9A binding agents28 Oct 2025US 12,453,770 B2Orionis Biosciences BV
- Activatable cytokine polypeptides and methods of use thereof27 Aug 2026US 2026/0250345 A1Werewolf Therapeutics, Inc.
- Methods for macrophage polarization23 Jul 2026US 2026/0209309 A1UniversitäT ZüRich
- Cd20 binding single domain antibodies16 Jul 2026US 2026/0201053 A1Universiteit Gent
- Gp130 binding molecules and methods of use25 Jun 2026US 2026/0176365 A1Synthekine, Inc.
- Clec9a binding agents7 May 2026US 2026/0124298 A1Orionis Biosciences BV
Most cited
By later US patents
- Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon27US 5,919,453 ALaboratoire European De Biotechnologie S.A. · 1999
- Antibodies binding the TNF related protein, TNF-X27US 7,060,800 B2Schering Corporation · 2006
- Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R).22US 6,787,634 B2Medisup International N.V. · 2004
- Treatment of inflammatory bowel disease with IFN-gamma inhibitors20US 7,300,656 B2Genentech, Inc. · 2007
- Treatment of inflammatory bowel disease with IFN-γ inhibitors20US 7,449,176 B2Genentech, Inc. · 2008